Platelet membrane-based and tumor-associated platelet-targeted drug delivery systems for cancer therapy

Review
  • 21 Downloads

Abstract

Platelets have long been known to play critical roles in hemostasis by clumping and clotting blood vessel injuries. Recent experimental evidence strongly indicates that platelets can also interact with tumor cells by direct binding or secreting cytokines. For example, platelets have been shown to protect circulating cancer cells in blood circulation and to promote tumor metastasis. In-depth understanding of the role of platelets in cancer progression and metastasis provides promising approaches for platelet biomimetic drug delivery systems and functional platelet-targeting strategies for effective cancer treatment. This review highlights recent progresses in platelet membrane-based drug delivery and unique strategies that target tumor-associated platelets for cancer therapy. The paper also discusses future development opportunities and challenges encountered for clinical translation.

Keywords

platelet-mimicking delivery systems tumor-associated platelets cancer therapy EPR effect 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

This work was supported by the National Distinguished Young Scientists Program (No. 31325010), the National Natural Science Foundation of China (No. 31730032), the Innovation Research Group of National Natural Science Foundation of China (No. 11621505), and the Key Research Project of Frontier Science of the Chinese Academy of Sciences (No.QYZDJ-SSW-SLH022).

References

  1. 1.
    Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 2008; 453(7193): 314–321CrossRefPubMedGoogle Scholar
  2. 2.
    Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005; 115(12): 3355–3362CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ho-Tin-Noé B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 2008; 68(16): 6851–6858CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11(2): 123–134CrossRefPubMedGoogle Scholar
  5. 5.
    Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19(11): 1423–1437CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mammadovabach E, Zigrino P, Brucker C, Bourdon C, Freund M, Arcangelis AD, Abrams SI, Orend G, Gachet C, Mangin PH. Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell–derived ADAM9. JCI Insight 2016; 1(14): e88245Google Scholar
  7. 7.
    Yu LX, Yan L, Yang W, Wu FQ, Ling Y, Chen SZ, Tang L, Tan YX, Cao D, Wu MC, Yan HX, Wang HY. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein. Nat Commun 2014; 5: 5256CrossRefPubMedGoogle Scholar
  8. 8.
    Xu P, Zuo H, Chen B, Wang R, Ahmed A, Hu Y, Ouyang J. Doxorubicin-loaded platelets as a smart drug delivery system: an improved therapy for lymphoma. Sci Rep 2017; 7: 42632CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci 2008; 13: 3532–3548PubMedGoogle Scholar
  10. 10.
    Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59(6): 1295–1300PubMedGoogle Scholar
  11. 11.
    Wang C, Sun W, Ye Y, Hu Q, Bomba HN, Gu Z. In situ activation ofplatelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nat Biomed Eng 2017; 1: 0011CrossRefGoogle Scholar
  12. 12.
    Daly ME. Determinants of platelet count in humans. Haematologica 2011; 96(1): 10–13CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Li J, Sharkey CC, Wun B, Liesveld JL, King MR. Genetic engineering of platelets to neutralize circulating tumor cells. J Control Release 2016; 228: 38–47CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hu CM, Fang RH, Wang KC, Luk BT, Thamphiwatana S, Dehaini D, Nguyen P, Angsantikul P, Wen CH, Kroll AV, Carpenter C, Ramesh M, Qu V, Patel SH, Zhu J, Shi W, Hofman FM, Chen TC, Gao W, Zhang K, Chien S, Zhang L. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 2015; 526(7571): 118–121CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dehaini D, Wei X, Fang RH, Masson S, Angsantikul P, Luk BT, Zhang Y, Ying M, Jiang Y, Kroll AV, Gao W, Zhang L. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater 2017 29(16):1606209CrossRefGoogle Scholar
  16. 16.
    Hu Q, Sun W, Qian C, Wang C, Bomba HN, Gu Z. Anticancer platelet-mimicking nanovehicles. Adv Mater 2015; 27(44): 7043–7050CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hu Q, Qian C, Sun W, Wang J, Chen Z, Bomba HN, Xin H, Shen Q, Gu Z. Engineered nanoplatelets for enhanced treatment of multiple myeloma and thrombus. Adv Mater 2016; 28(43): 9573–9580CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hu Q, Sun W, Qian C, Bomba HN, Xin H, Gu Z. Relay drug delivery for amplifying targeting signal and enhancing anticancer efficacy. Adv Mater 2017; 29(13): 1605803CrossRefGoogle Scholar
  19. 19.
    Li J, Ai Y, Wang L, Bu P, Sharkey CC, Wu Q, Wun B, Roy S, Shen X, King MR. Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. Biomaterials 2016; 76: 52–65CrossRefPubMedGoogle Scholar
  20. 20.
    Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, Sood AK, Afshar-Kharghan V. Platelets increase the proliferation of ovarian cancer cells. Blood 2012; 120(24): 4869–4872CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cooke NM, Spillane CD, Sheils O, O’Leary J, Kenny D. Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion. BMC Cancer 2015; 15(1): 627CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Klement GL, Yip TT, Cassiola F, Kikuchi L, Cervi D, Podust V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E, Almog N, Kieran MW, Folkman J. Platelets actively sequester angiogenesis regulators. Blood 2009; 113(12): 2835–2842CrossRefPubMedGoogle Scholar
  23. 23.
    Rachidi S, Metelli A, Riesenberg B, Wu BX, Nelson MH, Wallace C, Paulos CM, Rubinstein MP, Garrett-Mayer E, Hennig M, Bearden DW, Yang Y, Liu B, Li Z. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol 2017; 2(11): 7911CrossRefGoogle Scholar
  24. 24.
    Zhang Y, Wei J, Liu S, Wang J, Han X, Qin H, Lang J, Cheng K, Li Y, Qi Y, Anderson GJ, Sukumar S, Li S, Nie G. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics 2017; 7(5): 1062–1071CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ho-Tin-Noé B, Goerge T, Wagner DD. Platelets: guardians of tumor vasculature. Cancer Res 2009; 69(14): 5623–5626CrossRefPubMedGoogle Scholar
  26. 26.
    Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006; 103(4): 855–860CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Li S, Zhang Y, Wang J, Zhao Y, Ji T, Zhao X, Ding Y, Zhao X, Zhao R, Li F, Yang X, Liu S, Liu Z, Lai J, Whittaker AK, Anderson GJ, Wei J, Nie G. Nanoparticle-enabled local depletion of tumorassociated platelets disrupts tumor vascular barriers and augments tumor drug accumulation. Nat Biomed Eng 2017;1:667–679CrossRefGoogle Scholar
  28. 28.
    Ishikawa S, Miyashita T, Inokuchi M, Hayashi H, Oyama K, Tajima H, Takamura H, Ninomiya I, Ahmed AK, Harman JW, Fushida S, Ohta T. Platelets surrounding primary tumor cells are related to chemoresistance. Oncol Rep 2016; 36(2): 787–794CrossRefPubMedGoogle Scholar

Copyright information

© Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.College of Pharmaceutical ScienceJilin UniversityChangchunChina
  2. 2.CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in NanoscienceNational Center for Nanoscience and TechnologyBeijingChina
  3. 3.University of Chinese Academy of SciencesBeijingChina

Personalised recommendations